Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab to Prevent Psoriasis Relapse After NBUVB
NCT00050661Phase 2Completed
- Sponsor
- The Rockefeller University
- Start
- Oct 1997
- Primary completion
- Apr 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Psoriasis vulgaris (PV) comparing Daclizumab with Placebo (2 arms). Primary endpoint: Time to disease relapse. Started Oct 1997; status: completed.
02
Drugs
daclizumab
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT00050661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050661.